Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.720 +0.100 (+1.31%)
Streaming Delayed Price Updated: 2:52 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Peering Into WAVE Life Sciences's Recent Short Interest
 
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-09-03: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
Via Stocktwits
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Insights into WAVE Life Sciences's Upcoming Earnings
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For WAVE Life Sciences
 
Via Benzinga
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Crude Oil Falls Over 2%; Campbell's Earnings Top Estimates
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earnings
 
Via Benzinga
Which stocks are moving before the opening bell on Wednesday?
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss WAVE Life Sciences Stock
 
Via Benzinga
Wave (WVE) Q2 Revenue Drops 56%
Via The Motley Fool
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shares
Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress. 
Via Chartmill
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Where WAVE Life Sciences Stands With Analysts
 
Via Benzinga
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline 
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.